Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tramadol + diclofenac is a fixed-dose combination analgesic used for the management of moderate to severe pain, including acute musculoskeletal pain, postoperative pain, and acute flares of osteoarthritis or rheumatoid arthritis[1][2][8]. This combination leverages two complementary mechanisms of action for synergistic pain relief. Tramadol is an atypical opioid that acts as a μ-opioid receptor agonist and inhibits the reuptake of serotonin and norepinephrine in the central nervous system, reducing afferent pain signaling and amplifying inhibitory pathways[1]. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX)-1 and COX‑2 enzymes, thereby blocking prostaglandin synthesis responsible for inflammation and nociceptive pain[6]. The combination provides both immediate (from tramadol) and sustained (from diclofenac) analgesia. Clinical studies have shown this fixed-dose combination to be effective with a favorable safety profile compared to other combinations such as tramadol-paracetamol[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tramadol + diclofenac.